Navigation Links
iBio, Inc. Receives Anticipated Notice from NYSE MKT that Company is Below Certain Continued Listing Standards
Date:3/4/2013

develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems may include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more. Additional benefits may include: surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products by increasing potency and lengthening duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

Forward-Looking Statements 

Various statements in this release concerning iBio's future expectations, plans and prospects, including without limitation, iBio's ability to regain compliance with the continued listing standards on a timely basis constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, without limitation, iBio's failure to make progress consistent with the plan approved by the Exchange or iBio's failur
'/>"/>

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
2. iBio, Inc. and GE Healthcare form new global alliance
3. iBio, Inc. Prices $10 Million Public Offering
4. iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards
5. Zyomyx, Inc. Receives ISO 13485: 2003 Certification
6. New Science Fiction Novel Paints Terrifying Picture of Dystopian Future: Young Author Receives Glowing Reviews
7. Rosemary Gladstar Receives First-Annual ABC Mark Blumenthal Herbal Community Builder Award
8. Next Breath Receives ISO/IEC 17025:2005 Accreditation from the American Association for Laboratory Accreditation
9. OsteoFab™ Patient Specific Cranial Device Receives 510(k) Approval
10. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
11. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 30, 2014 Two ... America were hosted by Charm Sciences at its ... their week in the US, the participants discussed ... control, hygiene management, and process verification, and received ... , This was the first visit to the ...
(Date:10/31/2014)... October 31, 2014 Following the successful ... free learning webinar to introduce its new product and ... and biostatisticians. , Launched in September, Formedix On Demand ... of clinical trial automation tools. For the first time, ... browser. And by introducing Formations – a revolutionary new ...
(Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
Breaking Biology Technology:Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3
... ST PETER PORT, Guernsey and LONDON, July 6 ... to Drive Novel Antibiotics Platform Addressing,Areas of Major Unmet Need, ... Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor ... ("CP2"), today announces its,investment in a majority shareholding in Novacta ...
... NEW BRUNSWICK, N.J., July 3 Johnson & Johnson (NYSE: ... its tender offer for all outstanding shares of common stock of ... (Eastern time) on July 2, 2009. The offer was conducted ... Merger Sub, Inc. , , The depositary for the tender ...
... , PHOENIX, July 2 As many as ... with an eating disorder because they,re ashamed to admit they ... Eating and Anxiety Disorders . Healthcare professionals, family members ... in males that may signify an eating disorder. Therefore, effective ...
Cached Biology Technology:Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 2Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 3Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 4Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 5Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 2Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 3Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 4Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 2
(Date:10/31/2014)... good for attracting species, but it may not be enough ... study has found. , The researchers surveyed two types of ... abundance of two insects that interact with them. They found ... and black walnut, they didn,t find a corresponding abundance of ... the walnuts and black cherries and a type of wasp ...
(Date:10/31/2014)... 30, 2014  HITLAB SM , a healthcare ... its inaugural HITLAB Innovators Summit SM on ... HITLAB will partner with the Clinton Foundation,s Health ... ProtoHack, Columbia Business School Alumni Club of ... Engineering and Operations Research, bringing together leaders in ...
(Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
... Institute of Nanoscience have discovered how to use the ... a chip. Based on this, they built a transport ... individually. To demonstrate this, the Delft researchers sorted the ... the University of Florida has called the Delft discovery ...
... working at the University of Bristol has found a ... food poisoning. Their work is reported in Nature Medicine. ... shown that one particular antibiotic ? fosfomycin ?can treat ... laboratory conditions. , Because it was not effective in ...
... Wegener Institute for Polar and Marine Research observed ... began in Ny-Ålesund on Svalbard. Monitoring instruments displayed ... found. Aerosols from eastern Europe have been transported ... large-scale weather situation. , Usually the air ...
Cached Biology News:Biological motors sort molecules one by one on a chip 2Record air pollution above the Arctic 2